Study Links E-Cigarette Bans to Increased Cigarette Sales

Apr.08.2022
Study Links E-Cigarette Bans to Increased Cigarette Sales
A new study suggests that state-level e-cigarette bans are associated with increased cigarette sales.

According to foreign media reports, a new study suggests that a national ban on e-cigarettes is linked to an increase in cigarette sales. The study, published in the scientific journal "Health Affairs," adds to mounting evidence that banning the sale of e-cigarettes may lead more people to revert back to smoking, which is less safe than using nicotine alternatives.

 

During a three-month study, it was found that an additional 3.4 million cigarette packs were sold through convenience stores across three states.

 

Researchers have used state-level cigarette sales data to discover that Massachusetts, which has implemented a complete ban on nicotine e-cigarettes, has seen a 7.5% increase in per capita cigarette sales compared to expectations. Rhode Island and Washington, which have enacted bans on non-tobacco flavored nicotine e-cigarettes, have an average estimated increase of 4.6% in per capita cigarette sales compared to expectations. Based on actual and estimated cigarette sales, the researchers suggest that an additional 3.4 million cigarette packs were sold in convenience stores across the three states during the three-month study period following the implementation of their respective bans.

 

The study was sponsored by Juul Labs, but has had little impact thus far, possibly due to the belief among many in the tobacco control field that research funded by the industry is biased. This debate may stem from decades of data suppression by big tobacco companies, which has recently resurfaced. For example, the Society for Research on Nicotine and Tobacco (SRNT) now explicitly prohibits industry-sponsored speakers from presenting at its conferences, a move that has led to resignations and condemnation of current tobacco control as "anti-scientific".

 

Researchers examined data from the fall of 2019, when legislators began paying attention to a series of mysterious lung diseases referred to as EVALI, which were quickly associated with e-cigarettes by politicians. Although by November 2019, the Centers for Disease Control and Prevention (CDC) had attributed most cases to contaminated illegal THC cartridges, state governments still stirred up panic and sought emergency bans, which in some cases became permanent.

 

In response to the EVALI outbreak, Massachusetts instituted an emergency ban on all nicotine e-cigarettes starting on September 24, 2019. Rhode Island and Washington followed suit, implementing four-month emergency bans on non-tobacco flavored nicotine e-cigarettes on October 4, 2019, and October 10, 2019, respectively. Massachusetts has since permanently banned the sale of flavored e-cigarette products, including menthol, while Rhode Island and Washington's emergency bans have expired, though a permanent flavor ban remains on the table.

 

Previous research has found similar results to those presented in health value papers.

 

The use of nicotine has not been linked to any diagnosis of EVALI in the field of medicine, but misinformation continues to spread. Under the guidance of sensationalist reporting by policymakers and the media, concerns over the rates of youth vaping have directly sparked fears over deadly vaping products. Misleading information is simple: youth are using e-cigarettes and, in some cases, dying from them. Over two years have passed since the outbreak, and the Centers for Disease Control and Prevention (CDC) in the US have yet to release any formal correction stating that nicotine e-cigarettes are not associated with lung injuries.

 

Previous research has yielded similar results to the findings of a health-focused paper. Co-authors from Boston University published an article in the Harm Reduction Journal indicating that misunderstandings surrounding EVALI (e-cigarette or vaping product use-associated lung injury) – which led to a ban in Massachusetts – appeared to have increased cigarette consumption across Boston. Moreover, Dr. Abigail Friedman from Yale University found in JAMA Pediatrics that after San Francisco banned flavored e-cigarettes and tobacco products, high schoolers in the city were more likely to smoke than their peers in other similar districts across the US.

 

(Source: Filter)

 

Restrictions on vaping products may have unintended consequences, including an increase in cigarette sales. While policymakers have focused on limiting access to e-cigarettes, they may inadvertently be pushing consumers back to traditional tobacco products. This is especially problematic given the well-documented health risks associated with smoking. It remains to be seen whether tighter regulations on vaping will have the intended impact of reducing nicotine addiction overall.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
US-listed vaping technology and manufacturing company Ispire Technology reported fiscal first-quarter 2027 revenue of $27.5 million on November 9, 2026, down 9.3% year over year but up 3.2% sequentially. Gross margin recovered to 16.2%, while its net loss widened to $6.4 million from $3.3 million a year earlier. Management attributed the sales decline primarily to tighter European vaping regulation and reduced distributor orders. Ispire is expanding manufacturing in Malaysia and negotiating an OEM/ODM agreement with a Southeast Asian vaping brand, with an announcement anticipated in January 2027. The company estimates that Malaysian manufacturing offers an approximately 25% US tariff advantage over China-based production. However, it continues to purchase products from Shenzhen Yi Jia Technology Co., Ltd., a manufacturer controlled by its chairman, and reported $52 million in non-current related-party payables at September 30.
company
Nov.11 by 2Firsts Perspectives
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
British American Tobacco (BAT)'s VELO brand launched the VELO WRKS nicotine pouch range in Sweden on November 2, 2026. The initial release features three Dual Can variants, each containing two separate flavours in a dual-compartment container. Each can holds 20 slim pouches with 8mg of nicotine per pouch and retails for SEK 52.99. According to VELO, the first release, Drop 1, is limited to 75,000 cans and will remain available until February 2027 or while stocks last. VELO positions WRKS as a platform for testing new product concepts and has introduced an online consumer feedback survey. EU trademark records show BAT applied to register VELO WRKS in March 2026 under Class 34, covering nicotine pouches, e-cigarettes, heated tobacco products and other tobacco-related goods.
product
Nov.03
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
Philip Morris Japan launched its fourth confirmed nationwide convenience-store discount campaign for IQOS ILUMA i devices in 2026 on October 26, cutting three models by as much as ¥2,000, or about $12.70. The campaign began one day after JT ended a promotion that reduced Ploom AURA to ¥1,480, or about $9.40. JT says Ploom's share of Japan's heated-products category rose from 10.9% in January 2024 to 18.3% in June 2026, a gain of 7.4 percentage points, while PMI says IQOS still held about 68% category share in the third quarter. At the same time, Japan's two-stage heated-tobacco tax adjustment has pushed stick prices higher, leaving device discounts as an increasingly important tool for lowering the upfront cost of customer acquisition.
Market
Oct.28
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24